Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT.

Goense L, Ruurda JP, Carter BW, Fang P, Ho L, Meijer GJ, van Hillegersberg R, Hofstetter WL, Lin SH.

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1742-1751. doi: 10.1007/s00259-018-4011-6. Epub 2018 Apr 16.

2.

Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.

Findlay JM, Gillies RS, Franklin JM, Teoh EJ, Jones GE, di Carlo S, Gleeson FV, Maynard ND, Bradley KM, Middleton MR.

Eur Radiol. 2016 Oct;26(10):3519-33. doi: 10.1007/s00330-016-4227-4. Epub 2016 Feb 16.

PMID:
26883329
3.

Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.

Kroese TE, Goense L, van Hillegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN.

Dis Esophagus. 2018 Dec 1;31(12). doi: 10.1093/dote/doy055.

PMID:
29917073
4.

Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.

Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW.

Clin Nucl Med. 2014 Oct;39(10):862-7. doi: 10.1097/RLU.0000000000000517.

PMID:
25140549
5.

FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.

Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH.

BMC Med Imaging. 2017 Jan 5;17(1):1. doi: 10.1186/s12880-016-0171-7.

6.

Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment 18F-FDG PET/CT Imaging.

Beukinga RJ, Hulshoff JB, van Dijk LV, Muijs CT, Burgerhof JGM, Kats-Ugurlu G, Slart RHJA, Slump CH, Mul VEM, Plukker JTM.

J Nucl Med. 2017 May;58(5):723-729. doi: 10.2967/jnumed.116.180299. Epub 2016 Oct 13.

7.

Dual-time point 18F-FDG PET/CT for the staging of oesophageal cancer: the best diagnostic performance by retention index for N-staging in non-calcified lymph nodes.

Park S, Paeng JC, Kang CH, Cheon GJ, Kang KW, Chung JK, Lee DS.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1317-1328. doi: 10.1007/s00259-018-3981-8. Epub 2018 Mar 3.

PMID:
29502309
8.

Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.

Voncken FEM, Aleman BMP, van Dieren JM, Grootscholten C, Lalezari F, van Sandick JW, Steinberg JD, Vegt E.

Strahlenther Onkol. 2018 Feb;194(2):156-163. doi: 10.1007/s00066-017-1217-7. Epub 2017 Oct 19.

PMID:
29051991
9.

Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer.

Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart RHJA, Plukker JTM.

Radiology. 2018 Jun;287(3):983-992. doi: 10.1148/radiol.2018172229. Epub 2018 Mar 14.

PMID:
29533721
10.

To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.

Huang JW, Yeh HL, Hsu CP, Lu YY, Chuang CY, Lin JC, Lin JF, Chang CF.

J Chin Med Assoc. 2015 Apr;78(4):229-34. doi: 10.1016/j.jcma.2014.11.003. Epub 2014 Dec 31.

11.

Role of 18F-FDG-PET/CT in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.

Sasaki K, Uchikado Y, Okumura H, Omoto I, Kita Y, Arigami T, Uenosono Y, Owaki T, Maemura K, Natsugoe S.

Anticancer Res. 2017 Feb;37(2):859-864.

PMID:
28179343
12.

Cervical ultrasonography has no additional value over negative 18F-FDG PET/CT scans for diagnosing cervical lymph node metastases in patients with oesophageal cancer.

Goense L, Meziani J, van Rossum PSN, Wessels FJ, Lam MGEH, van Hillegersberg R, Ruurda JP.

Eur Radiol. 2018 May;28(5):2031-2037. doi: 10.1007/s00330-017-5136-x. Epub 2017 Dec 7.

13.

The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.

van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH.

J Nucl Med. 2016 May;57(5):691-700. doi: 10.2967/jnumed.115.163766. Epub 2016 Jan 21.

14.

Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.

Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.

JAMA Surg. 2015 Jun;150(6):555-62. doi: 10.1001/jamasurg.2014.3867.

PMID:
25902198
15.

Effectiveness of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Computerized Tomography (PET-CT) Scan in Identifying Interval Metastases for Patients with Esophageal Cancer.

Gabriel E, Alnaji R, Du W, Attwood K, Kukar M, Hochwald S.

Ann Surg Oncol. 2017 Jun;24(6):1739-1746. doi: 10.1245/s10434-016-5754-6. Epub 2017 Jan 5.

PMID:
28058562
16.

PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.

Yuan H, Tong DK, Vardhanabhuti V, Law SY, Chiu KW, Khong PL.

Nucl Med Commun. 2016 Sep;37(9):947-55. doi: 10.1097/MNM.0000000000000527.

PMID:
27145438
17.

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.

Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB; SANO study group.

Lancet Oncol. 2018 Jul;19(7):965-974. doi: 10.1016/S1470-2045(18)30201-8. Epub 2018 Jun 1.

PMID:
29861116
18.

Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.

Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H.

Br J Surg. 2004 Aug;91(8):1004-9.

PMID:
15286962
19.

The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.

Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K.

Cancer. 2005 Jan 1;103(1):148-56.

20.

Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.

Katsoulis IE, Wong WL, Mattheou AK, Damani N, Chambers J, Livingstone JI.

Int J Surg. 2007 Dec;5(6):399-403. Epub 2007 Jun 3.

Supplemental Content

Support Center